ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

November 16, 2021 GMT

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Parkinson’s disease and the development strategy going forward.

Event:Stifel Healthcare Conference 2021
Presentation:Virtual live webcast
Date:Wednesday, November 17
Time:
9:20 a.m. EST
Webcast:Events section of the Yumanity website
ADVERTISEMENT
Event:Jefferies London Healthcare Conference
Presentation:Virtual on-demand webcast
Date:November 16 to 18
Time:
Thursday, November 18 at 3:00 a.m. EST
Webcast:Events section of the Yumanity website
ADVERTISEMENT
Event:Piper Sandler Annual Healthcare Conference
Presentation:Virtual on-demand webcast
Date:November 30 to December 2
Time:
Monday, November 22 at 10:00 a.m. EST
Webcast:Events section of the Yumanity website

An audio webcast of each presentation can be accessed through the Events section of the Company’s website at  yumanity.com/investor-relations/events-presentations. An archived replay of each webcast will also be available on the Company’s website.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is in clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit  www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006